Despite extra funding, the prolonged underinvestment in medical and healthcare infrastructure would present difficulties in staging an effective response to the COVID-19 pandemic in India.
The general opinion that the future epidemic in India would be worse if it is not adequately controlled is convinced by the continuing shortage of medical funding and healthcare infrastructure.
The country’s healthcare system is not prepared for such a crisis, with 8.5 hospital beds per 10,000 people and eight doctors per 10,000. Besides, the considerable inefficiency, instability, and acute lack of public sector healthcare delivery networks do not meet the rising needs of the population.
Moreover, there is still no meaningful health insurance coverage for more than 80 percent of the population and nearly 68 percent of Indians have minimal or no access to essential medicines.
Also, the availability of free drugs in public health facilities has decreased from 31.2 percent to 8.9 percent for inpatient treatment over the last two decades, and from 17.8 percent to 5.9 percent for outpatient treatment, as per a report by the Public Health Foundation of India.
It also said that Indian pharmaceuticals and healthcare industry development would be assisted by the government’s move to achieve universal health coverage status.
As the third-largest pharmaceutical market in the Asia-Pacific region, the improvement of the business climate and proposed healthcare reforms will be positive for innovative drugmakers and, as such, the market will continue to hold significant potential.